BLM treatment significantly increased malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) levels while reducing GSH and GPX4 levels and HO-1 activity in the BLM-treated group compared to the control and EMPA-treated groups. This evidence concerns the gene HMOX1 and Bloom syndrome.